



March 30, 2020

Aouatef Bellamine, PhD
Senior Scientific Manager
Lonza Inc.
412 Mt. Kemble Ave., Suite 200S
Morristown, NJ, 07960

Re: Docket FDA-2019-P-4670


Dear Dr. Bellamine:

This letter is in response to your citizen petition (FDA-2019-P-4670) received on October 4, 2019 in which you requested that the U.S. FDA amend 21 CFR §101.9(c)(6)(i) to include arabinogalactan to the list of “isolated or synthetic non-digestible carbohydrate(s),” based on its beneficial physiological effect on immune functioning.

In accordance with Title 21 of the *Code of Federal Regulations*, section 21 CFR 10.30(e)(2), this letter is to advise you that we have not been able to reach a decision on your petition within the first 180 days of its receipt because of other agency priorities and the limited availability of resources. When we complete our review of your petition, we will notify you of our decision.

Please let us know if you have any questions.

Sincerely,



Claudine Kavanaugh, PhD, MPH, RD
Director
Office of Nutrition
and Food Labeling
Center for Food Safety
and Applied Nutrition